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ARTICLE
Implementation of Standardized Clinical Processes for
TPMT Testing in a Diverse Multidisciplinary Population:
Challenges and Lessons Learned
Kristin W. Weitzel1,2,∗, D. Max Smith1,2, Amanda R. Elsey1,2,3, Benjamin Q. Duong1,2, Benjamin Burkley2, Michael Clare-Salzler4,5,
Yan Gong2, Tara A. Higgins6, Benjamin Kong7,†, Taimour Langaee2, Caitrin W. McDonough2, Benjamin J. Staley6, Teresa T. Vo8,†,
Dyson T. Wake9,†, Larisa H. Cavallari1,2 and Julie A. Johnson1,2
Although thiopurine S-methyltransferase (TPMT) genotyping to guide thiopurine dosing is common in the pediatric cancer pop-
ulation, limited data exist on TPMT testing implementation in diverse, multidisciplinary settings. We established TPMT testing
(genotype and enzyme) with clinical decision support, provider/patient education, and pharmacist consultations in a tertiary
medical center and collected data over 3 years. During this time, 834 patients underwent 873 TPMT tests (147 (17%) genotype,
726 (83%) enzyme). TPMT tests were most commonly ordered for gastroenterology, rheumatology, dermatology, and hema-
tology/oncology patients (661 of 834 patients (79.2%); 580 outpatient vs. 293 inpatient; P < 0.0001). Thirty-nine patients had
both genotype and enzyme tests (n = 2 discordant results). We observed significant differences between TPMT test use and
characteristics in a diverse, multispecialty environment vs. a pediatric cancer setting, which led to unique implementation
needs. As pharmacogenetic implementations expand, disseminating lessons learned in diverse, real-world environments will
be important to support routine adoption.
Clin Transl Sci (2018) 11, 175–181; doi:10.1111/cts.12533; published online on 19 January 2018.
Study Highlights
WHAT IS THE CURRENT KNOWLEDGE ON THE TOPIC?
✔ Clinical implementation of TPMT genotyping testing has
been described primarily in pediatric cancer populations.
WHAT QUESTION DID THIS STUDY ADDRESS?
✔ Do differences in TPMT test ordering and use exist
between a diverse, multidisciplinary patient population as
compared with a pediatric cancer population that may lead
to unique clinical implementation needs?
WHAT THIS STUDY ADDS TO OUR KNOWLEDGE
✔ Limited data are available regarding implementation
of TPMT testing in diverse patient populations. Our study
found that TPMT test ordering and use characteristics dif-
fered between a diverse, multidisciplinary patient popula-
tion vs. a pediatric cancer population. In addition, there
were meaningful differences between this diverse multidis-
ciplinary pharmacogenetics implementation as compared
with our initial implementation of CYP2C19 testing in an
inpatient, cardiac catheterization setting.
HOW THIS MIGHT CHANGE CLINICAL PHARMACOL-
OGY OR TRANSLATIONAL SCIENCE
✔ As pharmacogenetics is increasingly translated into
practice, dissemination of real-world experiences and
lessons learned with different types of implementations in
diverse settings is essential for adopting clinical pharmaco-
genetics across a wide range of settings.
Thiopurines (i.e., azathioprine, mercaptopurine, and thiogua-
nine) are used as antimetabolite cytotoxic and immuno-
suppressive drugs for treatment of certain types of malig-
nant (e.g., acute lymphoblastic leukemia (ALL)) and non-
malignant conditions, particularly in autoimmune disorders
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such as inflammatory bowel disease (IBD).1–3 Although thiop-
urines achieve a treatment response in up to 70% of patients
with nonmalignant conditions, their use is limited by the
potential for significant toxicity, including gastrointestinal (GI)
effects, rash, and the possibility of severe or life-threatening
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myelosuppression.4,5 In IBD, for example, more than 20%
of patients discontinue thiopurines because of drug-related
toxicities.4
The thiopurine S-methyltransferase (TPMT) enzyme, which
is encoded by the thiopurine S-methyltransferase (TPMT)
gene, is responsible for inactivating thiopurine drugs, with
an inverse relationship between TPMT enzyme activity and
formation of cytotoxic thioguanine nucleotide metabolites
with resultant toxicities.6 TPMT enzyme activity is affected
by polymorphisms in the TPMT gene, with the three most
common inactive TPMT alleles, TPMT*2, *3A, and *3C,
accounting for 90% of all variants. Nearly all patients who
inherit two inactive TPMT alleles (e.g., *2/*3A, *2/*3C; poor
metabolizers) experience severe or life-threatening myelo-
suppression with usual doses due to accumulation of toxic
thiopurine drugmetabolites.7–9 Patients who inherit one inac-
tive TPMT allele (e.g., *1/*2, *1/*3A; intermediate metaboliz-
ers) have higher levels of thioguanine nucleotide metabo-
lites and increased risk of myelosuppression as compared
with patients who are homozygous for wildtype TPMT alle-
les (*1/*1; normal metabolizers). TPMT enzyme function can
also be assessed using an enzymatic assay (i.e., TPMT
phenotyping) that measures the rate at which methy-
lated products (6-mMP (methyl-mercaptopurine) or 6-mTGN
(methyl-thioguanine)) are formed in erythrocytes.10 For initial
assessment, providers may order one or both tests, keeping
in mind instances in which a specific test may be inappropri-
ate, such as TPMT genotyping in patients who have under-
gone liver transplant or TPMT phenotyping in patients who
have received a recent blood transfusion.
Prospective trials in pediatric patients with ALL have
demonstrated that TPMT genotype-guided therapy is asso-
ciated with reduced thiopurine toxicity without reduction
in efficacy.11,12 In patients with IBD and other nonmalig-
nant conditions, genotype-guided thiopurine dosing has also
been shown to reduce adverse drug events, with up to a
10-fold decrease in hematologic toxicities in patients who
have a TPMT variant as compared with nonvariant carriers.5
In addition to its routine inclusion in pediatric cancer treat-
ment protocols, treatment guidelines for multiple nonmalig-
nant conditions recommend preemptive use of TPMT geno-
typing and/or phenotyping to guide thiopurine dosing.13–15
Clinical Pharmacogenetics Implementation Consortium
(CPIC) guidelines provide detailed recommendations for use
of TPMT genotype data to guide thiopurine dosing in clin-
ical practice.8 These guidelines align well with implemen-
tation of TPMT genotyping in cancer treatment settings, in
which the genotype test is used nearly exclusively in the
inpatient setting due to the presence of disease and treat-
ment factors in this population that decrease the accuracy of
phenotyping.16 Published descriptions of TPMT genotyping
implementations in specialized cancer and/or pediatric prac-
tice settings also exist.17–21 However, the current practice-
based guidance and/or published experience descriptions
provide little guidance for clinicians implementing TPMT
genotype and/or phenotype testing in diverse, multispecialty
(primarily noncancer) populations.22 Practical guidance for
implementation of TPMT testing is especially important for
a variety of reasons. These include that in noncancer popu-
lations, thiopurine dosing is variable for different conditions
(and therefore differing needs for TPMT-based dose adjust-
ments). Additionally, prescribers may not be familiar with
TPMT testing and there may be confusion about choosing
between the TPMT genotype and/or phenotype assay test-
ing in these populations. Although TPMT phenotype test-
ing has historically been the predominant method to assess
TPMT enzyme function in noncancer settings, we anticipate
that TPMT genotyping will be increasingly adopted outside
of the pediatric cancer population as testing costs decrease
and pharmacogenetic implementations become increasingly
common.23,24 It is important to identify practice-based barri-
ers and clinician needs with implementation of routine order-
ing and interpretation of TPMT testing in diverse, multispe-
cialty populations.
The University of Florida (UF) Health Personalized
Medicine Program (PMP), a multidisciplinary clinical imple-
mentation initiative, was established in 2012 with imple-
mentation of CYP2C19 genotyping to guide antiplatelet
therapy in patients undergoing percutaneous coronary
intervention.23,25 Although TPMT genotyping and/or phe-
notyping were performed in individual specialty practices
at UF Health prior to 2012, a system-wide approach to
coordinate test ordering and interpretation did not exist.
In 2014, the UF Health PMP developed and implemented
a standardized process for TPMT testing that included
discipline-specific provider education; guidance on TPMT
test ordering and interpretation (for genotype and/or pheno-
type testing); clinical decision support within the electronic
health record (Epic); and standardized patient education
materials. We hypothesized that because of differences in
practice settings and providers, frequency of TPMT geno-
type test vs. phenotype (enzymatic) assay ordering, and
clinical use of thiopurines, unique needs would emerge for
system-wide implementation of a TPMT testing program in
a diverse, multidisciplinary noncancer practice environment
as compared with implementation in a specialized pediatric
hematology/oncology setting. In this article, we describe the
process for system-wide implementation of TPMT testing
in our institution, compare the use of TPMT genotyping and
phenotyping in diverse multidisciplinary practice settings vs.
a pediatric hematology/oncology setting, and examine the
concordance between TPMT genotype and phenotype test
results in patients who underwent both tests.
METHODS
Development of TPMT testing service
UF Health Shands Hospital is a 1,692-bed tertiary aca-
demic medical center affiliated with the University of Florida
and UF Physicians Outpatient Clinics. The health system’s
areas of excellence include cancer specialties, heart care,
women and children’s services, neuromedicine specialties,
and transplant services and houses the UF Health Shands
Cancer Hospital and UF Health Shands Children’s Hospital.
TPMT genotype and phenotype test ordering and reporting
procedures have historically varied among different practice
settings. In most cases, TPMT tests were ordered by individ-
ual providers through Prometheus Laboratories (San Diego,
CA), with a test turnaround time of 7 to 14 days (includ-
ing refrigerated sample shipping time plus test turnaround
time of 2–3 days from time of sample receipt). Prometheus
Clinical and Translational Science
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test results were faxed to the provider and scanned into the
“media” section of the electronic health record (EHR) by nurs-
ing staff. The Prometheus laboratory results reported TPMT
genotype using star-allele nomenclature with assignment of
phenotype (e.g., normal enzyme activity) and TPMT enzyme
assay results reported numerically, in EU (enzyme units) with
reference ranges, and graphically, in a visual representation
of TPMT enzyme activity along a spectrum of low, interme-
diate, or normal ranges.
Development of a standardized system-wide approach to
TPMT ordering and interpretation began in August 2013.23
At the time, the UF Health Shands Hospital Pharmacy and
Therapeutics (P & T) Committee provided oversight to a
PMP subcommittee and regulatory governance for clini-
cal pharmacogenetic implementations. As a first step for
this implementation, we identified clinical services that
commonly ordered TPMT testing (i.e., pediatric hematol-
ogy/oncology, gastroenterology, rheumatology, neurology,
dermatology, and internal medicine). Individual meetings
were then conducted with prescribers and nursing staff on
these services to determine current TPMT ordering proce-
dures and obtain feedback on clinical needs to improve
the TPMT testing process. Prescribers from all disciplines
were invited to participate in PMP subcommittee meetings to
develop therapeutic recommendations (Figure 1) and clinical
decision support (CDS) language.
Therapeutic recommendations and CDS alert language
were approved by the P & T Committee in November 2013,
although strategies for CDS alerts and clinical follow-up con-
tinued to evolve throughout the study period. An Epic Best
Practice Advisory (BPA, Figure 2) was built to fire in the pres-
ence of an actionable TPMT genotype in the EHR and a new
order for a thiopurine for all clinical services. A pretest alert
triggered by a new thiopurine order in a patient without a
known TPMT genotype result was built for pediatric hema-
tology/oncology services only (subsequent alerts were not
suppressed after initially firing for all alerts). When a CDS alert
fired, the PMP pharmacogenetics resident was notified via an
Epic in-basketmessage and provided awritten or verbal con-
sultation for actionable results, depending on the clinical ser-
vice. During the study period, PMP created additional Epic
in-basket messages to notify the pharmacogenetics resident
about phenotype test orders and/or results. If a phenotype-
related in-basket message was received, the resident
contacted the prescriber by email to determine if a clinical
consult was needed. If so, the resident provided recommen-
dations according to the prescriber’s preferred communica-
tion method (e.g., verbal consultation, email consultation, or
written note).
In addition to previous outreach and consultations with
individual providers, UF Health PMP pharmacists conducted
individual or group (e.g., grand rounds) educational ses-
sions with clinical staff and prescribers prior to the launch
of the clinical implementation in February 2014. Provider
education was individualized based on discipline-specific
guideline recommendations for testing and treatment with
thiopurines, historical use of TPMT genotype or phenotype
testing within each setting, current clinical workflow and
test-ordering procedures, and differences in patient popu-
lations. Written patient education materials were provided to
prescribers and staff and were available in PDF form acces-
sible through a hyperlink in the BPA in Epic.
Genotyping
UF Health PMP worked with the UF Health Pathology
Laboratory (UFHPL), a College of American Pathologists-
accredited Clinical Laboratory Improvement Amendments-
licensed (CAP/CLIA) clinical laboratory to develop and val-
idate TPMT genotype testing (enzymatic testing was not
offered by UFHPL). The TPMT assay is a laboratory-
developed test using quantitative polymerase chain reaction
(qPCR) through the Viia7 Real-Time PCR System (Applied
Biosystems by Life Technologies, Foster City, CA) to deter-
mine gene variants based on analysis of genomic DNA
extracted from either peripheral blood or buccal cells.
Development and validation of genotyping for TPMT*2,
*3A,*3B,*3C alleles was completed in January 2014. TPMT
genotype results expressed as phenotypes were provided
in the BPA based on CPIC guidelines, with patients classi-
fied as TPMT “normal metabolizers” (i.e., *1/*1), “intermedi-
ate metabolizers” (e.g., *1/*2, *1/*3A), or “poor metabolizers”
(e.g., *2/*3A, *2/*3C).6,26
Data collection and analysis
A standardized institutional process for TPMT testing and
clinical decision support was launched on 3 February 2014,
throughout the health system. TPMT tests (genotype and/or
phenotype) are performed in all settings as clinical test(s),
consistent with the established standard of care within that
practice setting. UF Health PMP is alerted via Epic to TPMT
genotype and phenotype orders and provides written phar-
macogenetic consultations for patients. Electronic data col-
lection included number and type of TPMT tests ordered, test
turnaround time, discipline/practice setting of ordering pre-
scriber, patient status at the time of order (inpatient vs. outpa-
tient), and demographics of patients who underwent TPMT
testing. For patients who had both genotype and phenotype
results, manual data collection was performed to identify fac-
tors that could affect the accuracy of the TPMT enzyme test
(i.e., sample age, history of allogeneic bone marrow trans-
plant, red blood cell (RBC) transfusions within 90 or 120
days, uremia, indication, and drug interactions).9,16,21,27–29
Chi-square and Fisher’s exact test were used for categorical
variables, as appropriate. The Wilcoxon rank-sum test com-
pared TAT between the genotype and enzyme tests. Data col-
lection processes were approved by the University of Florida
Institutional Review Board.
RESULTS
Between 3 February 2014, and 3 February 2017, 834
patients underwent 873 TPMT tests, consisting of 147
(17%) genotype tests and 726 (83%) enzyme tests
(Table 1). As expected based on the use characteristic of
thiopurines in the study populations, patients on the hema-
tology/oncology service were younger than those on non-
hematology/oncology services. Sex, race, and ethnicity also
differed between patients on the hematology/oncology ser-
vice vs. nonhematology/oncology services. The clinical ser-
vices that most commonly ordered a TPMT genotype or
www.cts-journal.com
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Figure 1 Clinical decision support algorithm for TPMT genotyping. AZA, azathiopurine; EHR, electronic health records; 6-MP, mercap-
topurine; TG, thioguanine; TPMT, thiopurine methyltransferase.
Figure 2 Sample Epic best practice advisory alert for TPMT genotype testing. TPMT, thiopurine methyltransferase.
phenotype test were gastroenterology, rheumatology, der-
matology, hematology/oncology, and allergy/immunology
(Table 2). Overall, the enzyme assay was ordered most
often to assess TPMT metabolism phenotype. However,
there were notable differences in the type of test ordered
by service. Patients assigned to the hematology/oncology
service were more likely to have genotype testing alone
as compared with those on other clinical services: 95%
(39 of 41) of hematology/oncology patients vs. 9% (69 of
793) of nonhematology/oncology; P < 0.0001). In contrast,
among patients tested by the gastroenterology, rheumatol-
ogy, or dermatology services, 87% (542 of 620 patients) had
only enzyme testing ordered. Both a genotype and enzyme
test were ordered for 39 patients, with dual-test orders
occurring most frequently on the gastroenterology service
(n= 24 of 39 patients; 62%). TPMT testing was ordered more
often in the outpatient setting as compared with the inpa-
tient setting overall (580 outpatient orders vs. 293 inpatient
orders; P < 0.0001). However, hematology/oncology service
providers ordered TPMT genotype testing more frequently in
the inpatient setting; 95%of tests from hematology/oncology
vs. 60% of tests from other providers were for inpatients;
P < 0.0001.
Among genotyped patients, 88% (n = 130) were normal
metabolizers, 12% (n = 17) intermediate metabolizers (n = 7
hematology/oncology service, n = 5 GI service, and n = 5
other services), and none were poor metabolizers. Pheno-
type frequencies based on enzyme testing were consis-
tent with frequencies based on genotype testing, with 85%
(n = 617) of patients classified as having normal enzyme
activity and the remaining 15% (n = 109) as low, interme-
diate, or abnormal activity (result reporting nomenclature
Clinical and Translational Science
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Table 1 Characteristics of patients on the hematology/oncology service vs.
other services who had TPMT testing
Hem/Onc Non -Hem/Onc
Characteristicb (n = 41a) (n = 793a)
Age, median (IQR), years 5.28 (3.28, 10.77) 37.99 (24.06, 55.67)
Sex, n (%)
Male 28 (68.29) 259 (32.66)
Race, n (%)
White 21 (51.2) 592 (74.7)
Black 9 (22.0) 147 (18.5)
Other 10 (24.4) 47 (5.9)
Unknown 1 (2.4) 7 (0.9)
Ethnicity, n (%)
Not Hispanic 29 (70.7) 736 (92.8)
Hispanic 12 (29.3) 49 (6.2)
Unknown 0 8 (1.0)
IQR, interquartile range.
aReflects total number of patients tested; 39 patients received both tests
(n = 873 TPMT tests ordered for 834 patients).
bP < 0.0001.
differed by laboratory). Test turnaround time was shorter for
genotyping than phenotyping (5 days (IQR 3–7 days) vs.
6 days (IQR 5–8 days)); P < 0.0001). Of the 39 patients
who underwent both genotyping and phenotyping, test
results were discordant in two (5%) patients. Both discordant
patients were male, treated on the gastroenterology service,
genotyped as TPMT *1/*1, and classified as intermediate
metabolizers according to phenotype assay results. At the
time of enzyme testing, concomitant medications in patients
with discordant test results included naproxen for one patient
and mesalamine and hydrocortisone for the other patient.
Fifty-four percent of patients who underwent TPMT test-
ing (n = 450 of 834 patients) received a thiopurine dur-
ing the 3-year data collection period. Conversely, out of
1,323 patients who received a thiopurine between 3 Febru-
ary 2014, to 31 December 2016 (data unavailable for entire
study period), 807 (61%) underwent TPMT testing. In patients
who received a thiopurine, mercaptopurine was used most
often in hematology/oncology patients (n = 33 of 38; 87%),
while azathioprine was used most frequently on other clinical
services (n = 356 of 412; 86%). For all patients on the
hematology/oncology service with an actionable TPMT
genotype, thiopurines were appropriately dose-adjusted
based on genotype according to the patient’s chemother-
apy treatment protocol, as directed in the BPA (similar data
are unavailable for nonhematology/oncology patients due to
EHR limitations).
DISCUSSION
The above results demonstrate significant differences in the
ordering and use of the TPMT genotype test vs. pheno-
typing assay within a diverse, multispecialty patient popu-
lation as compared with TPMT testing characteristics in a
primarily pediatric cancer population. Over a 3-year period,
the majority of TPMT tests in our institution were ordered
by nonhematology/oncology providers in the outpatient set-
ting, with patients more likely to undergo TPMT pheno-
type testing as compared with TPMT genotyping. Genotype–
phenotype discordance was observed at a rate of 5% in
patients who underwent both tests, which is consistent with
discordance studies in large populations.30,31 Both patients
who had discordant test results were also taking medi-
cation(s) that could potentially inhibit the TPMT enzyme,
although data are conflicting regarding the clinical relevance
of drug-induced TPMT enzyme inhibition.21,32,33 At the end
of the study period, one discordant patient received azathio-
prine with a genotype-guided dose and the other patient did
not receive a thiopurine. Use of genotype to guide thiopurine
dosing in discordant patients is consistent with study find-
ings that support increased accuracy of the TPMT genotype
test as compared with the phenotype assay. In a large analy-
sis of genotype–phenotype discordance, researchers found
TPMT genotyping to be more reliable than phenotyping and
recommended its use over the TPMT phenotype assay if only
one test could be performed.30
The predominance of TPMT orders by nonpediatric hema-
tology/oncology providers observed in our study is consis-
tent with TPMT testing data in a diverse pediatric patient
population from Manzi et al. at Boston Children’s Hospital,
who reported that over a 2-year period, nearly 90% (317 of
355) of TPMT test orders in their institution were placed by
GI specialists.19 This finding supports the need to engage
both hematology/oncology and nonhematology/oncology
Table 2 TPMT test orders for patients by specialty
Genotype only, n
(n = 108)
Phenotype only, n
(n = 687)
Genotype and
phenotype, n
(n = 39)
TPMT test order
rate, mean
test(s)/month
Gastrointestinal 42 425 24 14
Rheumatology 11 61 0 2
Dermatology 1 56 0 1.6
Hematology/oncology 39 1 1 1.2
Allergy/immunology 2 35 1 1.1
Hospitalist 1 18 4 0.75
Internal medicine 3 18 1 0.64
Neurology 1 14 4 0.64
Pulmonary/critical care 1 11 1 0.4
Others 7 48 3 1.7
Test order rate was calculated as the sum of patients with any TPMT test ordered by a service divided by 36 months (3 February 2014 to 3 February 2017).
www.cts-journal.com
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providers prior to TPMT implementation. In addition, we
observed discipline-specific differences in CDS develop-
ment and clinical support needs. For malignant conditions,
prescribers preferred a pretest alert and written consult
note with each actionable genotype, but requested that
BPA language refer to the patient’s chemotherapy treatment
protocol instead of CPIC recommendations due to minor
differences between CPIC- and protocol-recommended
genotype-guided dosing. For nonmalignant conditions, pre-
scribers supported CPIC-recommended dose adjustments.
However, due to concerns about workflow efficiency, alert
fatigue, and differences in Epic documentation of genotype
and phenotype test results, these prescribers opted not to
have a TPMT pretest alert or written consultation notes from
PMPwith each actionable genotype. Instead, they requested
outreach by PMP upon actionable genotype results, with
case-by-case determination of the level of clinical support
needed. We also observed areas of concordance among the
varying specialties in CDS development. Because of BPA
space limits and a universal prescriber preference to mini-
mize BPA text, prescribers worked together to reach consen-
sus on essential information to include in the BPA. In addi-
tion, all specialties supported not suppressing subsequent
alerts after the initial firing due to the anticipated rarity of an
alert firing and identification of instances in which it would
be desirable for it to fire multiple times (e.g., provider orders
thiopurine but is unaware of an existing TPMT result linked
to a previous date/patient encounter in the EHR).
In addition to discipline-specific needs that emerged, the
predominant use of phenotyping vs. genotyping in nonhema-
tology/oncology patients also impacted the implementation
process. Within our institution, phenotype results are ordered
from a variety of commercial laboratories with variable ref-
erence ranges and most often documented as scanned
media files vs. discrete variables. Because of this, we were
not able to link CDS alerts to an “actionable” phenotype
result. Instead, PMP used the in-basket messaging system to
detect TPMT phenotype orders and provide clinical support
as needed, such as assisting with test interpretation or iden-
tifying inappropriate use of phenotyping (e.g., recent blood
transfusion).
Finally, this wide range of clinical specialties translated
to diverse provider education needs. To address this, we
developed different educational strategies based on prac-
tice needs and aligned with historic use of TPMT testing.
Identified provider educational gaps included inconsistent
knowledge of discipline-specific evidence-based recom-
mendations for thiopurine dosing, unfamiliarity with TPMT
genotyping (as comparedwith predominant use of phenotyp-
ing in nonhematology/oncology patients), confusion regard-
ing which TPMT test to order and how to interpret discordant
test results, and variable needs for support staff education
with workflow changes in TPMT test ordering and resulting
processes.
We also experienced differences in this implementation
as compared with our initial development of CYP2C19
testing in an inpatient, cardiac catheterization setting.25
The TPMT implementation’s inclusion of both inpatient and
outpatient settings required engagement of two distinct
CDS approval and build processes, vs. an inpatient-only
process with CYP2C19 implementation. We also observed
differences in regulatory oversight. Within our institution, the
P & T committee regulates inpatient medication use pro-
cesses only, so while this group was sufficient to oversee
CYP2C19 implementation, support of TPMT testing required
PMP to engage with outpatient Medication Safety and Epic
committees. Our regulatory structure has since been for-
mally revised to accommodate subsequent pharmacoge-
netic implementations, with the PMP Committee now exist-
ing as a standalone institutional committee with inpatient and
outpatient representation.
These findings and lessons learned have important impli-
cations as clinical pharmacogenetic testing is implemented
with increased frequency in diverse, multidisciplinary envi-
ronments across a range of specialties and settings. Within
our institution, changes to the clinical implementation pro-
cess that were developed with TPMT laid the ground-
work for our program to meet a wide range of future
needs for subsequent pharmacogenetic implementations,
including CYP2D6 testing for opioids in pain management,
CYP2D6 and CYP2C19 testing for SSRI therapy in psychi-
atry, and CYP2C19 testing to guide proton pump inhibitor
and voriconazole use across multiple specialty popula-
tions. As pharmacogenetic implementations become more
widespread within diverse, multispecialty institutions, these
considerations can inform the development of other pharma-
cogenetic implementations.
CONCLUSION
This study revealed significant diversity in the use and
application of TPMT testing to thiopurine dosing within
a large, multidisciplinary population that included cancer
and noncancer patients and revealed unique CDS, reg-
ulatory, and provider education needs for pharmacoge-
netic implementations within our institution. As pharmacoge-
netic implementations become increasingly common among
diverse practice settings, disseminating unique character-
istics and lessons learned regarding diverse implementa-
tions will be essential to support routine adoption of clinical
pharmacogenetics.
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